Current Report · Items 2.02, 7.01, 9.01 · 8-K

Eikon Therapeutics, Inc.

EIKNNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Regulation FD Disclosure

Item 2.02 Results of Operations and Financial Condition. On May 11, 2026, Eikon Therapeutics, Inc. (the "Company") issued a press release announcing clinical and corporate updates and its financial results for the quarter ended March 31, 2026 (the “Press Release”). A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Filed May 11, 2026Accepted May 11, 2026, 4:05 PM EDTCIK 1861123Accession 0001193125-26-216744

View company →Permanent SEC source ↗

Company context

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications. We believe our product candidates reflect strong scientific and clinical potential and could eventually become critical medicines in the treatment paradigm of various cancers.

Current securities

EIKNNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On May 11, 2026, the Company updated its corporate presentation. A copy of the updated presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in Items 2.02 and 7.01, including Exhibits 99.1 and 99.2 hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Filed exhibits (2)

EX-99.1 (by filename) eikn-ex99_1.htm

EX-99.1 2 eikn-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates • Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026 • Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor • Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data • Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking (SMT) to advance chemical matter for discovery programs in the absence of robust biochemical assays • Roger M. Perlmutter, Board Chair and CEO, to participate in the Bank of America Securities 2026 Global Healthcare Conference in Las Vegas, May 12, 2026 MILLBRAE, Calif., May 11, 2026 -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late…

Open exhibit ↗

EX-99.2 (by filename) eikn-ex99_2.htm

EX-99.2 3 eikn-ex99_2.htm EX-99.2 Q2 Company Presentation May 2026 Exhibit 99.2 Disclaimer Any statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning the strategy, initiation, cost, timing, progress, and results of our preclinical studies and clinical trials for our product candidates; our ability to leverage our technology platform to enable more informed drug research and development; estimates of the number of patients with certain diseases and conditions we intend to treat, the number of patients that we plan to enroll in our clinical trials, and the size and nature of the market opportunity for our product candidates, expected milestones and business objectives for 2026 and beyond, including our anticipated presentations at the 2026 annual meeting of the American Society of Clinical Oncology ("ASCO"); and our ability to maintain our current license agreements and collaborations, including our ability to comply with our financial obligations pursuant to the terms of such …